Laropiprant

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameLaropiprant
Drug Alias NameLaropiprantum拉罗皮兰拉罗匹仑L-888839MK-0524
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstaglandin D2 receptor antagonists
TargetsProstaglandin D2 receptor
Therapy Area/IndicationsFlushingHypercholesterolemiaDyslipidemias +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Frosst Canada LtdMerck & Co IncMerck Sharp & Dohme LLC +[5] 
Active IndicationsN/A
Inactive IndicationsFlushingHypercholesterolemiaDyslipidemias +[9] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG